For better or worse: The effect of Levodopa on speech in Parkinson's disease

Movement Disorders

Volumn 23, Issue 4, 2008, Pages 574-580

  Ho, Aileen K ^a   Bradshaw, John L ^b   Iansek, Robert ^c  

^a UNIVERSITY OF READING   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c Kingston Centre   (Australia)

Author keywords

Duration; Intensity; Levodopa; Parkinson's disease; Speech; Volume or intensity decay

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ACOUSTICS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHONIA; LIMB MOVEMENT; LOUDNESS; MALE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PITCH; PRIORITY JOURNAL; PROGNOSIS; SPEECH ANALYSIS; SPEECH ARTICULATION; SPEECH DISORDER; STIMULUS RESPONSE; THERAPY EFFECT; TREATMENT PLANNING; DRUG EFFECT; HOSPITALIZATION; LARYNX DISORDER; MIDDLE AGED; SPEECH; VERBAL BEHAVIOR;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SPEECH; SPEECH DISORDERS; VERBAL BEHAVIOR; VOICE DISORDERS;

EID: 43549111102     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21899     Document Type: Article

References (60)

1. Wu T, Hallett M. A functional MRI study of automatic movements in patients with Parkinson's disease. Brain 2005;128:2250-2259.
2. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkinson's disease: neural correlates of voice treatment revealed by PET. Neurology 2003;60:432-440.
3. Riecker A, Mathiak K, Wildgruber D, et al. fMRI reveals two distinct cerebral networks subserving speech motor control. Neurology 2005;64:700-706.
4. Sanabria J, Ruiz PG, Gutierrez R, et al. The effect of levodopa on vocal function in Parkinson's disease. Clin Neuropharmacol 2001; 24:99-102.
5. Goberman AM, Coelho C. Acoustic analysis of parkinsonian speech. I. Speech characteristics and L-Dopa therapy. NeuroRehabilitation 2002;17:237-246.
6. Schulz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature. J Commun Disord 2000;33:59-88.
7. Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson's disease. Lancet Neurol 2004;3:547-556.
8. Forrest K, Weismer G, Turner GS. Kinematic, acoustic, and perceptual analyses of connected speech produced by parkinsonian and normal geriatric adults. J Acoust Soc Am 1989;85:2608-2622.
9. Connor NP, Abbs JH, Cole KJ, Gracco VL. Parkinsonian deficits in serial multiarticulate movements for speech. Brain 1989;112 (Part 4):997-1009.
10. Ackermann H, Grone BF, Hoch G, Schonle PW. Speech freezing in Parkinson's disease: a kinematic analysis of orofacial movements by means of electromagnetic articulography. Folia Phoniatr (Basel) 1993;45:84-89.
11. Forrest K, Weismer G. Dynamic aspects of lower lip movement in parkinsonian and neurologically normal geriatric speakers' production of stress. J Speech Hear Res 1995;38:260-272.
12. Ackermann H, Hertrich I, Daum I, Scharf G, Spieker S. Kinematic analysis of articulatory movements in central motor disorders. Mov Disord 1997;12:1019-1027.
13. Netsell R, Cleeland CS. Modification of lip hypertonia in dysarthria using EMG feedback. J Speech Hear Disord 1973;38:131-140.
14. Hunker CJ, Abbs JH, Barlow SM. The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: a quantitative analysis. Neurology 1982;32:749-754.
15. Baker KK, Ramig LO, Luschei ES, Smith ME. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology 1998;51:1592-1598.
16. Ackermann H, Ziegler W. Articulatory deficits in parkinsonian dysarthria: an acoustic analysis. J Neurol Neurosurg Psychiatry 1991;54:1093-1098.
17. Ho AK, Iansek R, Bradshaw JL. The effect of a concurrent task on Parkinsonian speech. J Clin Exp Neuropsychol 2002;24:36-47.
18. Ho AK, Bradshaw JL, Cunnington R, Phillips JG, Iansek R. Sequence heterogeneity in Parkinsonian speech. Brain Lang 1998; 64:122-145.
19. Gath I, Yair E. Analysis of vocal tract parameters in parkinsonian speech. J Acoust Soc Am 1988;84:1628-1634.
20. Smith ME, Ramig LO, Dromey C, Perez KS, Samandari R. Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. J Voice 1995;9:453-459.
21. Alexander GE, Crutcher MD. Preparation for movement: neural representations of intended direction in three motor areas of the monkey. J Neurophysiol 1990;64:133-150.
22. Evarts EV, Wise SP. Basal gangalia outputs and motor control. Ciba Foundation Symp 1984;107:83-102.
23. Morris ME, Iansek R, Matyas TA, Summers JJ. The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 1994;117 (Part 5):1169-1181.
24. Oliveira RM, Gurd JM, Nixon P, Marshall JC, Passingham RE. Micrographia in Parkinson's disease: the effect of providing external cues. J Neurol Neurosurg Psychiatry 1997;63:429-433.
25. Ho AK, Iansek R, Bradshaw JL. Regulation of parkinsonian speech volume: the effect of interlocuter distance. J Neurol Neurosurg Psychiatry 1999;67:199-202.
26. Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson's disease: effects of implicit cues and explicit instructions. Neuropsychologia 1999;37:1453-1460.
27. Ramig LO. How effective is the Lee Silverman voice treatment? Asha 1997;39:34-35.
28. Brotchie P, Iansek R, Horne MK. Motor function of the monkey globus pallidus. I. Neuronal discharge and parameters of movement. Brain 1991;114 (Part 4):1667-1683.
29. Brotchie P, Iansek R, Horne M. A neural network model of neural activity in the monkey globus pallidus. Neurosci Lett 1991;131: 33-36.
30. Martin KE, Phillips JG, Iansek R, Bradshaw JL. Inaccuracy and instability of sequential movements in Parkinson's disease. Exp Brain Res 1994;102:131-140.
31. Iansek R, Bradshaw JL, Phillips JG, Cunnington R, Morris ME. Interaction of the basal ganglia and supplementary motor area in the elaboration of movement. Adv Psychol (Amsterdam) 1995;111: 37-60.
32. Konczak J, Ackermann H, Hertrich I, Spieker S, Dichgans J. Control of repetitive lip and finger movements in Parkinson's disease: influence of external timing signals and simultaneous execution on motor performance. Mov Disord 1997;12:665-676.
33. Agostino R, Berardelli A, Curra A, Accornero N, Manfredi M. Clinical impairment of sequential finger movements in Parkinson's disease. Mov Disord 1998;13:418-421.
34. Ho AK, Iansek R, Bradshaw JL. Motor instability in parkinsonian speech intensity. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:109-116.
35. Logemann JA, Fisher HB, Boshes B, Blonsky ER. Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Disord 1978;43:47-57.
36. Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with Parkinson's disease. Behav Neurol 1998;11:131-137.
37. Kent RD, Kim YJ. Toward an acoustic typology of motor speech disorders. Clin Linguist Phon 2003;17:427-445.
38. Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001;16:79-83.
39. Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 2005;20: 205-221.
40. Fox CM, Farley BG, Ramig LA, McFarland D. An integrated rehabilitation approach to Parkinson's disease: learning big and loud. Movement Disorders 2005;20:S149.
41. Aparicio P, Diedrichsen J, Ivry RB. Effects of focal basal ganglia lesions on timing and force control. Brain Cogn 2005;58:62-74.
42. Iansek R, Huxham F, McGinley J. The sequence effect and gait festination in Parkinson disease: contributors to freezing of gait? Mov Disord 2006;21:1419-1424.
43. Mawdsley C, Gamsu CV. Periodicity of speech in Parkinsonism. Nature 1971;231:315-316.
44. De Letter M, Vantens P, Van Borsel J. The effects of levodopa on word intelligibility in Parkinson's disease. J Commun Disord 2005;38:187-196.
45. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
46. Kokmen E, Naessens JM, Offord KP. A short test of mental status - description and preliminary results. Mayo Clin Proc 1987; 62:281-288.
47. Fahn S, Elton RL, Committee Ud. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan; 1987. p 153-163.
48. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
49. Carson CP, Ingrisano DR, Eggleston KD. The effect of noise on computer-aided measures of voice: a comparison of CSpeechSP and the multi-dimensional voice program software using the CSL 4300B module and multi-speech for windows. J Voice 2003;17: 12-20.
50. Butter-worth B. Evidence from pauses in speech. In: Butterworth B, editor. Language production. London: Academic Press; 1980. p 155-176.
51. Larson K, Ramig L, Scherer R. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson's disease. J Med Speech Lang Pathol 1994;2:227-239.
52. Daniels N, Oates J, Phyland DJ, Feiglin A, Hughes A. Vocal characteristics and response to levodopa in Parkinson's disease. Mov Disord 1996; 11 (Suppl 1): 117.
53. Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458-462.
54. Viallet F, Teston B, Ludovic J, et al. Effects of pharmacological versus electrophysiological treatments on Parkinsonian dysprosody. In Speech Prosody, April 11-13, Aix-en-Provence, 2002.
55. Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 1999;109:1287-1294.
56. Schulz GM. The effects of speech therapy and pharmacological treatments on voice and speech in Parkinson s disease: a review of the literature. Curr Med Chem 2002;9:1359-1366.
57. Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002;35:217-239.
58. Colosimo C, Merello M, Hughes A, Sieradzan K, Lees A. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996; 60:634-637.
59. McColl CD, Reardon KA, Shift M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002;17: 1227-1234.
60. Fox CM, Ramig LO. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech Lang Pathol 1997;6:85-94.